<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02787954</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-MS-14-0761</org_study_id>
    <nct_id>NCT02787954</nct_id>
  </id_info>
  <brief_title>Prospective Tumor Response Evaluation</brief_title>
  <acronym>Liver</acronym>
  <official_title>Prospective Evaluation of Tumor Response to Cancer Treatment Therapies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if MRI imaging can detect genetic, proteomic, and
      metabolomic characteristics of liver tumors. The study also aims to determine if these
      imaging characteristics are correlated with clinical outcomes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For each treatment arm, pre-procedural MRI and post procedural MRI will be obtained.
      Pre-procedural biopsies will be obtained, if possible. Pretreatment genetic expression,
      proteomic, or metabolomic patterns from the tumor samples will be assessed. Imaging
      characteristics from tumors will be extracted using automated softwareâ€”the study will apply a
      computational analysis system with the capability to extract and analyze imaging
      characteristics and correlate them to genetic expression, proteomic, and metabolomic tumor
      characteristics. Imaging findings will be correlated to clinical outcomes and genetic,
      proteomic, and metabolomic findings to determine association. Imaging findings and genomic,
      proteomic, and metabolomic tumor characteristics will be correlated to clinical outcomes
      (time to recurrence, overall survival, 3-month, 6-month, and 1-year survival).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">January 2026</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Time to progression</measure>
    <time_frame>1 month to 3 years</time_frame>
    <description>Time from initial treatment to progression as defined by RECIST criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>1 year survival</measure>
    <time_frame>1 year</time_frame>
    <description>Number of patients alive 1 year after treatment</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Hepatocellular Cancer</condition>
  <condition>Metastatic Liver Cancer</condition>
  <arm_group>
    <arm_group_label>Transcatheter Chemoembolization or TACE</arm_group_label>
    <description>A technique called transcatheter chemoembolization (TACE) is used for some patients with liver cancer that cannot be treated surgically. The procedure is a way of delivering cancer treatment directly to a tumor through minimally-invasive means.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Yittrium 90 or Y-90</arm_group_label>
    <description>Radioembolization is a minimally invasive procedure that combines embolization and radiation therapy to treat liver cancer. Tiny glass or resin beads filled with the radioactive isotope yttrium Y-90 are placed inside the blood vessels that feed a tumor. This blocks the supply of blood to the cancer cells and delivers a high dose of radiation to the tumor while sparing normal tissue.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Microwave Ablation or MWA</arm_group_label>
    <description>Microwave ablation (MWA), destroys liver tumors using heat generated by microwave energy. A CT scan or ultrasonic guidance is used to pinpoint the exact location of the tumor. A thin antenna, which emits microwaves, is then inserted into the tumor. The probe produces intense heat that ablates (destroys) tumor tissue, often within 10 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>electroporation</arm_group_label>
    <description>Irreversible electroporation (IRE) is a nonthermal method of destroying the cell. A cell is subjected to a powerful electrical field using high-voltage direct current (up to 3 kV); this creates multiple holes in the cell membrane and irreversibly damages the cell's homeostasis mechanism, leading to instant cell death.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TACE</intervention_name>
    <description>Procedure for giving chemotherapy directly to tumor cells.</description>
    <arm_group_label>Transcatheter Chemoembolization or TACE</arm_group_label>
    <other_name>Transcatheter arterial chemoembolization</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Y-90</intervention_name>
    <description>Using a combination of radiation and chemotherapy directly on the tumor cells to cause cell death.</description>
    <arm_group_label>Yittrium 90 or Y-90</arm_group_label>
    <other_name>Yittrium 90</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>MWA</intervention_name>
    <description>Using heat to kill tumor cells.</description>
    <arm_group_label>Microwave Ablation or MWA</arm_group_label>
    <other_name>Microwave Ablation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>IRE</intervention_name>
    <description>Using energy to disrupt tumor cell activity, thereby causing cellular death.</description>
    <arm_group_label>electroporation</arm_group_label>
    <other_name>Irreversible Electroporation</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Biopsy liver tumor samples and blood tumor samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with primary or metastatic liver cancer, who are deemed candidates for TACE,
        electroporation, MWA, or Y90 will be enrolled. The patients will be recruited from medical
        oncology, surgical oncology, gastroenterology, and transplant surgery services.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis or suspicion of primary or metastatic liver cancer deemed eligible for TACE,
             Y-90, percutaneous ablation, and /or electroporation.

        Exclusion Criteria:

          -  Any reason MRI cannot be obtained.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Derek L West, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas Healtlh Science Center at Houston</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Derek L. West, MD</last_name>
    <phone>713-704-4972</phone>
    <email>derek.l.west@uth.tmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Karen P Swaby, BSN</last_name>
    <phone>713-704-2842</phone>
    <email>karen.p.swaby@uth.tmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Texas Health Science Center Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012 Mar 31;379(9822):1245-55. doi: 10.1016/S0140-6736(11)61347-0. Epub 2012 Feb 20. Review.</citation>
    <PMID>22353262</PMID>
  </reference>
  <reference>
    <citation>Gu L, Liu H, Fan L, Lv Y, Cui Z, Luo Y, Liu Y, Li G, Li C, Ma J. Treatment outcomes of transcatheter arterial chemoembolization combined with local ablative therapy versus monotherapy in hepatocellular carcinoma: a meta-analysis. J Cancer Res Clin Oncol. 2014 Feb;140(2):199-210. Review.</citation>
    <PMID>24077865</PMID>
  </reference>
  <reference>
    <citation>Raoul JL, Gilabert M, Piana G. How to define transarterial chemoembolization failure or refractoriness: a European perspective. Liver Cancer. 2014 May;3(2):119-24. doi: 10.1159/000343867. Review.</citation>
    <PMID>24945002</PMID>
  </reference>
  <reference>
    <citation>Assumpcao L, Choti M, Pawlik TM, Gecshwind JF, Kamel IR. Functional MR imaging as a new paradigm for image guidance. Abdom Imaging. 2009 Nov;34(6):675-85. doi: 10.1007/s00261-008-9481-8. Epub 2008 Dec 2. Review.</citation>
    <PMID>19048335</PMID>
  </reference>
  <reference>
    <citation>Bian DJ, Xiao EH, Hu DX, Chen XY, Situ WJ, Yuan SW, Sun JL, Yang LP. Magnetic resonance spectroscopy on hepatocellular carcinoma after transcatheter arterial chemoembolization. Chin J Cancer. 2010 Feb;29(2):198-201.</citation>
    <PMID>20109351</PMID>
  </reference>
  <reference>
    <citation>Minami Y, Kudo M. Therapeutic response assessment of transcatheter arterial chemoembolization for hepatocellular carcinoma: ultrasonography, CT and MR imaging. Oncology. 2013;84 Suppl 1:58-63. doi: 10.1159/000345891. Epub 2013 Feb 20. Review.</citation>
    <PMID>23428860</PMID>
  </reference>
  <reference>
    <citation>Karlo CA, Di Paolo PL, Chaim J, Hakimi AA, Ostrovnaya I, Russo P, Hricak H, Motzer R, Hsieh JJ, Akin O. Radiogenomics of clear cell renal cell carcinoma: associations between CT imaging features and mutations. Radiology. 2014 Feb;270(2):464-71. doi: 10.1148/radiol.13130663. Epub 2013 Oct 28.</citation>
    <PMID>24029645</PMID>
  </reference>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 26, 2016</study_first_submitted>
  <study_first_submitted_qc>May 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 1, 2016</study_first_posted>
  <last_update_submitted>May 26, 2016</last_update_submitted>
  <last_update_submitted_qc>May 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Derek Lamont West</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

